Filing Details

Accession Number:
0001209191-20-019682
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-03-17 17:16:13
Reporting Period:
2020-03-16
Accepted Time:
2020-03-17 17:16:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1305253 Eiger Biopharmaceuticals Inc. EIGR Biological Products, (No Disgnostic Substances) (2836) 361004130
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1670382 S Jeffrey Glenn 350 Cambridge Ave, Suite 350
Palo Alto CA 94306
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-03-16 30,000 $5.03 66,355 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 460 Indirect By son
Common Stock 151,064 Indirect By Eiger Group International, Inc.
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.89 to $5.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  2. Shares are held by Eiger Group International, Inc. ("EGI"). The Reporting Person is the Chief Executive Officer of EGI and has sole power to vote and sole power to dispose of shares directly owned by EGI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.